Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Nubolic Max Grape Seed Forte 60000mg - TGA Drug Approval Details

Approvals/TGA/Nubolic Max Grape Seed Forte 60000mg

Approved

STANDARD

Nubolic Max Grape Seed Forte 60000mg

Aus Nature Pharmaceuticals Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Date: May 29, 2025
Approval ID: 54db9a08831620e1
Company: Aus Nature Pharmaceuticals Pty Ltd
Type: Standard

Approval Details

Approval Id: 54db9a08831620e1
Product Name: Nubolic Max Grape Seed Forte 60000mg
Artg Id: 273243
Artg Name: Nubolic Max Grape Seed Forte 60000mg
Sponsor: Aus Nature Pharmaceuticals Pty Ltd
Artg Date: 2016-03-22
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: LI

Active Ingredients

Approved

Quick Info

Agency

TGA

Country

🇦🇺

Approval Date

May 29, 2025

Approval ID

54db9a08831620e1

Type

Standard

Back to TGA Approvals